Six Important PMCF Mistakes Medical Device Manufacturers Should Avoid
According to the new European Medical Device Regulation (EU MDR), Post-Market Surveillance (PMS) activities will become crucial for identifying and investigating potential residual risks of medical devices after they have been taken to market. Such risks should be tracked and assessed through systematic Post-Market Clinical Followup (PMCF).
As the MDR deadline in May 2021 approaches, manufacturers with devices which previously obtained compliance based on equivalence with another device already on the market must now conduct proactive PMCF studies to reassess their residual risks to ensure compliance.
While PMCF will increase costs of PMS in the short term, it can also be seen as an opportunity for alignment of processes across the operational portfolio in the long term. Proactive PMCF system can be leveraged to not only gather data for compliance, but also to gain more comprehensive market insights and product marketing claims.
In this Slide Deck, we outline 6 pitfalls to avoid when conducting your PMCF activities including
We hope that you will enjoy this Slide Deck. If you have any questions or feedback, please feel free to contact us at firstname.lastname@example.org.